
The European Medicines Agency (EMA) is a decentralised body of the European Union with headquarters in Amsterdam. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.
Unlock the market timeline & signal feed
New Partnerships activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
Survodutide Shows Promising Results in Obesity
Survodutide Shows Promising Results in Obesity
Sign up to see the full signal feed
How European Medicines Agency's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
European Medicines AgencyYou | 15 | 6 | +467% | 20 | 21 |
SNE/Scientific Specialist
View postingAmsterdam, North Holland, Netherlands · 4d ago
Clinical Trials Data management/Statistical Programming Specialist
View postingAmsterdam, North Holland, Netherlands · 4d ago
SNE/Biostatistician Specialist (evidence generation)
View postingAmsterdam, North Holland, Netherlands · last wk.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
EU launches pilot program for innovative medical devices and diagnostics in Q2, addressing regulatory modernization. Global healthcare trends include AI integration, trade policy impacts, and medical tourism expansion.
EMA recommends oral semaglutide for obesity treatment, but studies reveal significant muscle mass loss with GLP-1 medications, equivalent to 20 years of physiological aging.
Menarini Group and Stemline Therapeutics will present seven data presentations at 2026 ASCO Annual Meeting, covering elacestrant and tagraxofusp therapies for solid and hematologic cancers, including metastatic breast cancer and BPDCN.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about European Medicines Agency's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.